Veracyte Reports 2.8% ROE Amid Advanced Genomic Testing Portfolio
- Reports
- 7
- Developments
- 5
- Repetition
- 71%
New informationRepeats or wire copies
What happened
Veracyte is a global diagnostics company that provides advanced genomic tests for various conditions, including cancer. Based on trailing twelve months to March 2025, the company reported a Return on Equity (ROE) of 2.8%, calculated from US$33 million in net profit against US$1.2 billion in shareholders' equity.
From Zacks, Simply Wall St.
Why it matters
The company's advanced tests are designed to improve diagnostic and prognostic decisions, which may help patients avoid unnecessary procedures and reduce time to appropriate treatment. The company's financial metrics, such as ROE, are key factors for investors.
From Zacks, Simply Wall St.
Who's involved
- Veracyte (United States)Global diagnostics company providing advanced genomic tests
- San FranciscoLocation where Veracyte is headquartered
- Iglesia de San FranciscoCultural property sharing geographic context with Veracyte
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Veracyte (United States)Speculative
Healthcare providers might see changes in diagnostic costs due to the availability of Veracyte's advanced genomic tests.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.How it developed
Newest first. Tap a step to see who reported it.- Veracyte, Inc. secured reimbursement from Medicare for its diagnostic tests.Sub-event
- Veracyte presented Afirma GRID studies at the Endocrine Society Annual Meeting, which was held in San Francisco on July 9, 2025.Sub-event
- Helix and Veracyte announced a partnership on August 7, 2025, to expand access to genomic insights.Sub-event
Veracyte is headquartered in San Francisco and provides lab testing services across the US.1 source
Veracyte faces revenue concerns but sees growth from Nightingale and advances Umbrella trial.1 source
Keep exploring
The entities involved
-
Veracyte (United States)
company in South San Francisco, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksHere's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today For most investors, how much a stock's price changes over time is important. This factor can impact your investme
- ZacksIs the Options Market Predicting a Spike in Veracyte Stock? Investors in Veracyte, Inc. VCYT need to pay close attention to the stock based on moves in the options market lately. That is because the
- ZacksHere's Why Veracyte (VCYT) is a Strong Momentum Stock For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a g
- ZacksHere's Why Veracyte (VCYT) is a Strong Growth Stock It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investor
- ZacksVeracyte (VCYT) Tops Q2 Earnings and Revenue Estimates Veracyte (VCYT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to e
- Simply Wall St.Declining Stock and Decent Financials: Is The Market Wrong About Veracyte, Inc. (NASDAQ:VCYT)? With its stock down 21% over the past three months, it is easy to disregard Veracyte (NASDAQ:VCYT). Howe
- ZacksShould You Continue to Hold Veracyte Stock in Your Portfolio Now? Veracyte VCYT is making solid progress in its long-term growth drivers, including in its NIGHTINGALE study for nasal swabs. The compa